October 17, 2022

Ruppin synthesizes cross-field expertise to study synthetic lethality

Eytan Ruppin has won the ASBMB’s 2023 DeLano Award in Computational Biology.
Read More arrow arrow
October 6, 2022

Faces of Digital Health Podcast hosts Pangea Biomed CEO, Tuvik Beker

AI, Precision Oncology, and Understanding Cancer (Pangea Biomed)
Read More arrow arrow
September 25, 2022

Beginner’s Mind Podcast hosts Pangea Biomed CEO, Tuvik Beker

How to Start a Life Science Company in Israel and Raise Capital in Silicon Valley
Read More arrow arrow
September 6, 2022

Preprint of Pangea-led collaboration now on bioRxiv

Showcasing ENLIGHT's ability to improve both personalized oncology and clinical trial design.
Read More arrow arrow
July 13, 2022

New Collaborative Study Uses Pangea’s Platform to Create World’s First Sequencing-Free, Transcriptomics-Based Drug Response Predicting System

Published in bioRxiv, the study leverages Pangea Biomed’s ENLIGHT platform to develop a novel approach to precision cancer care that combines AI techniques and digital pathology, bypassing the need for expensive and time-consuming DNA and RNA sequencing
Read More arrow arrow
July 8, 2022

Meet the nominees for the 2022 VentureBeat Women in AI Awards!

Dr. Ranit Aharonov, Chief Technology Officer, Pangea Biomed was awarded the 2022 Women In AI Research award from VentureBeat.
Read More arrow arrow
May 19, 2022

Pangea appoints Dr. Ezra Cohen as Chairman of its Scientific Advisory Board

Dr. Cohen will lead Pangea's SAB as the company identifies the most impactful applications of ENLIGHT.
Read More arrow arrow
April 25, 2022

Neighborhood Watch: Pangea Pursues Group Approach to Precision Oncology

Israeli company emerges from stealth with seed funding touting “the next revolution in precision oncology”, powered by its ENLIGHT platform, designed to predict responses to therapies for dozens of cancers.
Read More arrow arrow
April 10, 2022

Israeli company debuts multi-cancer response predictor

Pangea Biomed Launches Multi-Cancer Response Predictor, Increasing cancer Patient Benefits from Precision Oncology by 5x.
Read More arrow arrow
April 7, 2022

Pangea Biomed reels in $7M for pan-cancer response predictor

Pangea Biomed Ltd. picked up $7 million in seed financing to fast-track the development of its multicancer, multitherapy response predictor ENLIGHT.
Read More arrow arrow